Management ChangeMay 6, 2026, 12:01 PM
Regenerex Pharma Terminates CFO Kenneth Perry for Cause
AI Summary
Regenerex Pharma, Inc. announced the termination of its Chief Financial Officer, Kenneth Perry, for Cause, effective May 2, 2026. This decision followed an administrative suspension initiated on March 31, 2026, and a comprehensive review by the Governance and Nominating Committee, which found a material and continuing breach of his Employment Agreement. Concurrently, Don E. Ray was appointed as Interim CFO on April 1, 2026, for an initial 90-day term.
Key Highlights
- Regenerex Pharma terminated Chief Financial Officer Kenneth Perry for Cause.
- Mr. Perry's employment termination was effective May 2, 2026, following an administrative suspension.
- The Board determined Mr. Perry's conduct constituted a material and continuing breach of his Employment Agreement.
- The Governance and Nominating Committee conducted a comprehensive review of relevant materials.
- Don E. Ray was appointed as Interim Chief Financial Officer on April 1, 2026.
- Mr. Ray's appointment as Interim CFO is for an initial term of 90 days.
Price Impact